Researchers have developed a unique type of nanoparticle called a “nanorattle” that greatly enhances light emitted from within its outer shell.
The starting gold nanosphere seeds (left) are surrounded by a hollow, porous silver cage (middle) and become a nanorattle filled with light-scattering dyes inside a gold outer shell (right). The nanorattles can amplify and detect signals from separate types of nanoprobes without needing an expensive machine or medical professional to read the results.
New nanoparticle shape can greatly enhance signals from multiple separate biomarkers at once, accurately detecting head and neck cancers without biopsies to improve global health
Researchers at Duke University have developed a unique type of nanoparticle called a “nanorattle” that greatly enhances light emitted from within its outer shell.
Loaded with light scattering dyes called Raman reporters commonly used to detect biomarkers of disease in organic samples, the approach can amplify and detect signals from separate types of nanoprobes without needing an expensive machine or medical professional to read the results.
In a small proof-of-concept study, the nanorattles accurately identified head and neck cancers through an AI-enabled point-of-care device that could revolutionize how these cancers and other diseases are detected in low-resource areas to improve global health.
The results appeared online September 2 in the Journal of Raman Spectroscopy.
“The concept of trapping Raman reporters in these so-called nanorattles has been done before, but most platforms had difficulty controlling the interior dimensions,” said Tuan Vo-Dinh, the R. Eugene and Susie E. Goodson Distinguished Professor of Biomedical Engineering and professor of chemistry at Duke.
“Our group has developed a new type of probe with a precisely tunable gap between the interior core and outer shell, which allows us to load multiple types of Raman reporters and amplify their emission of light called surface-enhanced Raman scattering,” Vo-Dinh said.
To make nanorattles, researchers start with a solid gold sphere about 20 nanometers wide. After growing a layer of silver around the gold core to make a larger sphere (or cube), they use a corrosion process called galvanic replacement that hollows out the silver, creating a cage-like shell around the core. The structure is then soaked in a solution containing positively charged Raman reporters, which are drawn into the outer cage by the negatively charged gold core. The outer hulls are then covered by an extremely thin layer of gold to lock the Raman reporters inside.
The result is a nanosphere (or nanocube) about 60 nanometers wide with an architecture that resembles a rattle—a gold core trapped within a larger outer silver-gold shell. The gap between the two is only about a few nanometers, which is just large enough to fit the Raman reporters.
Those tight tolerances are essential to controlling the Raman signal enhancement the nanorattles produce.
When a laser shines on the nanorattles, it travels through the extremely thin outer shell and hits the Raman reporters within, causing them to emit light of their own. Because of how close the surfaces of the gold core and the outer gold/silver shell are together, the laser also excites groups of electrons on the metallic structures, called plasmons. These groups of electrons create an extremely powerful electromagnetic field due to the plasmons’ interaction of the metallic core-shell architecture, a process called plasmonic coupling, which amplifies the light emitted by the Raman reporters millions of times over.
“Once we had the nanorattles working, we wanted to make biosensing devices to detect infectious diseases or cancers before people even know they’re sick,” Vo-Dinh said. “With how powerful the signal enhancement of the nanorattles is, we thought we could make a simple test that could be easily read by anybody at the point-of-care.”
In the new paper, Vo-Dinh and his collaborators apply the nanorattle technology to a lab-on-a-stick device capable of detecting head and neck cancers, which appear anywhere between the shoulders and the brain, typically in the mouth, nose and throat. Survival rate for these cancers have hovered between 40 and 60 percent for decades. While those statistics have improved in recent years in the United States, they have gotten worse in low-resource settings, where risk factors such as smoking, drinking and betel nut chewing are much more prevalent.
“In low-resource settings, these cancers often present in advanced stages and result in poor outcomes due in part to limited examination equipment, lack of trained healthcare workers and essentially non-existent screening programs,” said Walter Lee, professor of head and neck surgery & communication sciences and radiation oncology at Duke, and a collaborator on the research.
“Having the ability to detect these cancers early should lead to earlier treatment and improvement in outcomes, both in survival and quality of life,” Lee said. “This approach is exciting since it does not depend on a pathologist review and potentially could be used at the point of care.”
The prototype device uses specific genetic sequences that act like Velcro for the biomarkers the researchers are looking for — in this case, a specific mRNA that is overly abundant in people with head and neck cancers. When the mRNA in question is present, it acts like a tether that binds nanorattles to magnetic beads. These beads are then concentrated and held in place by another magnet while everything else gets rinsed away. Researchers can then use a simple, inexpensive handheld device to look for light emitted from the nanorattles to see if any biomarkers were caught.
In the experiments, the test determined whether or not 20 samples came from patients that had head and neck cancer with 100% accuracy. The experiments also showed that the nanorattle platform is capable of handling multiple types of nanoprobes, thanks to a machine learning algorithm that can tease apart the separate signals, meaning they can target multiple biomarkers at once. This is the goal of the group’s current project funded by the National Institutes of Health.
“Many mRNA biomarkers are overly abundant in multiple types of cancers, while other biomarkers can be used to evaluate patient risk and future treatment outcome,” Vo-Dinh said. “Detecting multiple biomarkers at once would help us differentiate between cancers, and also look for other prognostic markers such as Human Papillomavirus (HPV), and both positive and negative controls. Combining mRNA detection with novel nanorattle biosensing will result in a paradigm shift in achieving a diagnostic tool that could revolutionize how these cancers and other diseases are detected in low-resource areas”.
Source: Duke University news release. Author: Ken Kingery